|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FER |
Gene summary for FER |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FER | Gene ID | 2241 |
| Gene name | FER tyrosine kinase | |
| Gene Alias | PPP1R74 | |
| Cytomap | 5q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | P16591 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2241 | FER | CA_HPV_1 | Human | Cervix | CC | 2.15e-03 | -1.29e-01 | 0.0264 |
| 2241 | FER | CCI_2 | Human | Cervix | CC | 5.72e-03 | 5.68e-01 | 0.5249 |
| 2241 | FER | CCI_3 | Human | Cervix | CC | 6.13e-11 | 9.61e-01 | 0.516 |
| 2241 | FER | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.33e-10 | -5.43e-01 | 0.0155 |
| 2241 | FER | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.49e-03 | -4.81e-01 | -0.1808 |
| 2241 | FER | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.73e-05 | -5.76e-01 | -0.1207 |
| 2241 | FER | HTA11_696_2000001011 | Human | Colorectum | AD | 4.13e-13 | -3.96e-01 | -0.1464 |
| 2241 | FER | HTA11_866_2000001011 | Human | Colorectum | AD | 1.85e-02 | -2.90e-01 | -0.1001 |
| 2241 | FER | HTA11_1391_2000001011 | Human | Colorectum | AD | 6.50e-06 | -4.30e-01 | -0.059 |
| 2241 | FER | HTA11_866_3004761011 | Human | Colorectum | AD | 2.27e-10 | -5.74e-01 | 0.096 |
| 2241 | FER | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.93e-03 | -4.73e-01 | 0.0338 |
| 2241 | FER | HTA11_7696_3000711011 | Human | Colorectum | AD | 8.30e-10 | -4.43e-01 | 0.0674 |
| 2241 | FER | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.12e-08 | -4.37e-01 | 0.294 |
| 2241 | FER | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.46e-07 | -4.47e-01 | 0.3859 |
| 2241 | FER | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.15e-24 | -6.43e-01 | 0.3005 |
| 2241 | FER | A001-C-207 | Human | Colorectum | FAP | 9.59e-04 | -3.63e-01 | 0.1278 |
| 2241 | FER | A015-C-203 | Human | Colorectum | FAP | 1.76e-21 | -5.36e-01 | -0.1294 |
| 2241 | FER | A015-C-204 | Human | Colorectum | FAP | 4.08e-06 | -3.63e-01 | -0.0228 |
| 2241 | FER | A014-C-040 | Human | Colorectum | FAP | 3.21e-03 | -3.78e-01 | -0.1184 |
| 2241 | FER | A002-C-201 | Human | Colorectum | FAP | 4.97e-12 | -4.61e-01 | 0.0324 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
| GO:001081010 | Cervix | CC | regulation of cell-substrate adhesion | 69/2311 | 221/18723 | 8.57e-14 | 5.69e-11 | 69 |
| GO:00315898 | Cervix | CC | cell-substrate adhesion | 96/2311 | 363/18723 | 1.48e-13 | 8.85e-11 | 96 |
| GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
| GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
| GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
| GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
| GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
| GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
| GO:00071639 | Cervix | CC | establishment or maintenance of cell polarity | 63/2311 | 218/18723 | 4.25e-11 | 8.76e-09 | 63 |
| GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
| GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
| GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
| GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
| GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
| GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
| GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
| GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
| GO:004325410 | Cervix | CC | regulation of protein-containing complex assembly | 96/2311 | 428/18723 | 2.91e-09 | 3.05e-07 | 96 |
| GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0452020 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
| hsa04520110 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
| hsa04520 | Colorectum | AD | Adherens junction | 50/2092 | 93/8465 | 1.52e-09 | 2.83e-08 | 1.81e-08 | 50 |
| hsa045201 | Colorectum | AD | Adherens junction | 50/2092 | 93/8465 | 1.52e-09 | 2.83e-08 | 1.81e-08 | 50 |
| hsa045202 | Colorectum | SER | Adherens junction | 37/1580 | 93/8465 | 1.54e-06 | 2.35e-05 | 1.71e-05 | 37 |
| hsa045203 | Colorectum | SER | Adherens junction | 37/1580 | 93/8465 | 1.54e-06 | 2.35e-05 | 1.71e-05 | 37 |
| hsa045204 | Colorectum | MSS | Adherens junction | 42/1875 | 93/8465 | 6.18e-07 | 9.01e-06 | 5.52e-06 | 42 |
| hsa045205 | Colorectum | MSS | Adherens junction | 42/1875 | 93/8465 | 6.18e-07 | 9.01e-06 | 5.52e-06 | 42 |
| hsa045208 | Colorectum | FAP | Adherens junction | 45/1404 | 93/8465 | 8.66e-13 | 2.89e-10 | 1.76e-10 | 45 |
| hsa045209 | Colorectum | FAP | Adherens junction | 45/1404 | 93/8465 | 8.66e-13 | 2.89e-10 | 1.76e-10 | 45 |
| hsa0452010 | Colorectum | CRC | Adherens junction | 37/1091 | 93/8465 | 5.72e-11 | 6.37e-09 | 4.32e-09 | 37 |
| hsa0452011 | Colorectum | CRC | Adherens junction | 37/1091 | 93/8465 | 5.72e-11 | 6.37e-09 | 4.32e-09 | 37 |
| hsa0452025 | Endometrium | AEH | Adherens junction | 36/1197 | 93/8465 | 3.49e-09 | 5.98e-08 | 4.37e-08 | 36 |
| hsa04520111 | Endometrium | AEH | Adherens junction | 36/1197 | 93/8465 | 3.49e-09 | 5.98e-08 | 4.37e-08 | 36 |
| hsa0452026 | Endometrium | EEC | Adherens junction | 36/1237 | 93/8465 | 8.57e-09 | 1.48e-07 | 1.11e-07 | 36 |
| hsa0452035 | Endometrium | EEC | Adherens junction | 36/1237 | 93/8465 | 8.57e-09 | 1.48e-07 | 1.11e-07 | 36 |
| hsa0452030 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
| hsa04520114 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
| hsa0452014 | Liver | NAFLD | Adherens junction | 37/1043 | 93/8465 | 1.50e-11 | 1.64e-09 | 1.32e-09 | 37 |
| hsa0452015 | Liver | NAFLD | Adherens junction | 37/1043 | 93/8465 | 1.50e-11 | 1.64e-09 | 1.32e-09 | 37 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FER | SNV | Missense_Mutation | rs763459582 | c.556G>A | p.Val186Ile | p.V186I | P16591 | protein_coding | deleterious(0.05) | probably_damaging(0.97) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FER | SNV | Missense_Mutation | c.2126N>G | p.Glu709Gly | p.E709G | P16591 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| FER | SNV | Missense_Mutation | rs533871351 | c.362N>C | p.Ile121Thr | p.I121T | P16591 | protein_coding | deleterious(0.02) | benign(0.046) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FER | SNV | Missense_Mutation | novel | c.1598N>A | p.Thr533Lys | p.T533K | P16591 | protein_coding | tolerated(0.97) | benign(0.045) | TCGA-BH-A42T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FER | SNV | Missense_Mutation | c.281N>G | p.Ser94Cys | p.S94C | P16591 | protein_coding | deleterious(0.01) | possibly_damaging(0.554) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FER | SNV | Missense_Mutation | novel | c.1484N>A | p.Ser495Tyr | p.S495Y | P16591 | protein_coding | deleterious(0) | possibly_damaging(0.722) | TCGA-EW-A6SA-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| FER | SNV | Missense_Mutation | c.2207G>A | p.Arg736Lys | p.R736K | P16591 | protein_coding | tolerated(0.19) | probably_damaging(0.97) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
| FER | deletion | Frame_Shift_Del | novel | c.1357delN | p.Lys453SerfsTer16 | p.K453Sfs*16 | P16591 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| FER | SNV | Missense_Mutation | novel | c.2332C>T | p.Arg778Trp | p.R778W | P16591 | protein_coding | deleterious(0) | benign(0.267) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| FER | SNV | Missense_Mutation | c.2207N>C | p.Arg736Thr | p.R736T | P16591 | protein_coding | tolerated(0.07) | probably_damaging(0.993) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 328083505 | ||
| 2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | ALISERTIB | ALISERTIB | ||
| 2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 249565817 | ||
| 2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | TAMATINIB | R-406 | ||
| 2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | CENISERTIB | CENISERTIB | ||
| 2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | CYC-116 | CYC-116 | ||
| 2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | LINIFANIB | LINIFANIB | ||
| 2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | ENTRECTINIB | ENTRECTINIB | ||
| 2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
| 2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | CEDIRANIB | CEDIRANIB |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |